Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nplate® Pregnancy Exposure Registry (NPER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02090088
Recruitment Status : Terminated
First Posted : March 18, 2014
Results First Posted : January 6, 2015
Last Update Posted : January 6, 2015
Sponsor:
Information provided by (Responsible Party):
Amgen

Brief Summary:
US study to estimate the prevalence at birth of major birth defects (ie, those that cause significant functional or cosmetic impairment, require surgery, or are life-limiting) in children born to mothers who have received Nplate® therapy at any time during the pregnancy.

Condition or disease Intervention/treatment
Birth Defect Spontaneous Abortions Low Birth Weight Drug: Not applicable- observational study

Detailed Description:
The purpose of the NPER is to monitor pregnancies exposed to Nplate® and to detect and record serious adverse events in infants up to one year after birth. The lack of adequate human fetal safety data for Nplate® makes the NPER an important component of the pharmacovigilance program on the safety of this drug. With respect to fetal outcome, it is important to evaluate the spectrum of outcomes that may be relevant to a medication exposure during pregnancy, and these include both easily recognizable defects that are visible at birth, as well as more subtle or delayed defects that may not be readily identifiable without special expertise and observation beyond the newborn period.

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 4 participants
Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration: 21 Months
Official Title: Nplate® Pregnancy Exposure Registry (NPER)
Study Start Date : May 2009
Actual Primary Completion Date : January 2014
Actual Study Completion Date : January 2014

Group/Cohort Intervention/treatment
All Subjects
All Subjects
Drug: Not applicable- observational study



Primary Outcome Measures :
  1. Number of Children Born With Major Birth Defects [ Time Frame: At birth ]
    An external, independent Congenital Malformation Adjudication Panel (CMAP) comprised of two clinical dysmorphologists and/or teratologists organized malformations based upon organ system and embryology, and determined whether structural defects were major or minor according to a modification of the Metropolitan Atlanta Congenital Defects Program (MACDP) birth defect classification system. A major structural defect is defined as a defect which has either cosmetic or functional significance to the child (eg, a cleft lip), require surgery, or are life-limiting).


Secondary Outcome Measures :
  1. Number of Children Born With Any 3 or More Minor Birth Defects [ Time Frame: At birth ]
    An external, independent Congenital Malformation Adjudication Panel (CMAP) comprised of two clinical dysmorphologists and/or teratologists organized malformations based upon organ system and embryology, and determined whether structural defects were major or minor according to a modification of the Metropolitan Atlanta Congenital Defects Program (MACDP) birth defect classification system. A minor structural defect is defined as a defect which occurs in less than 4% of the population but which has neither cosmetic nor functional significance to the child (eg, complete 2,3 syndactyly of the toes).

  2. Number of Children Born With a Specific Pattern of Minor Birth Defects [ Time Frame: At birth ]
    Only those infants who have received medical evaluation and who have three or more minor defects will be considered "affected" for purposes of the evaluation of a pattern of minor defects.

  3. Number of Participants With Spontaneous and Elective Abortions or Stillbirths [ Time Frame: 9 months (during pregnancy) ]
    Number of each of spontaneous abortions, elective abortions, and stillbirths among mothers who received Nplate® therapy at any time during the pregnancy.

  4. Number of Children With Preterm Birth or Low Birth Weight [ Time Frame: At birth ]
    Number of children with preterm birth (<37 weeks gestation) or low birth weight (<2,500 grams) among children born to mothers who have received Nplate® therapy at any time during the pregnancy.

  5. Number of Children Born With Intrauterine Growth Restriction [ Time Frame: At birth ]
    Number of children born with intrauterine growth restriction (weight, length or head circumference less than tenth percentile for sex and gestational age) among mothers who have received Nplate® therapy at any time during the pregnancy.

  6. Number of Infants With Adverse Events [ Time Frame: 12 months from birth ]
    In the first year of life, the incidence of all serious adverse events, as well as of nevi (birthmarks) and angiomata (benign tumors with blood vessels or lymph vessels), among infants whose mothers received Nplate® therapy at any time during the pregnancy.

  7. Number of Participants With Adverse Events [ Time Frame: Throughout pregnancy and for up to 6 weeks after delivery ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The study population consists of two cohorts of women and their offspring who reside in the U.S. The exposed cohort is defined as pregnant women who have received at least one dose of Nplate® during pregnancy and their offspring up to one year of age. The unexposed cohort is defined as women unexposed to Nplate® during pregnancy matched on disease status (cITP) and age (childbearing) to the exposed. In order to provide context for any possible Nplate® exposed women without cITP, comparators from published literature will be used.
Criteria

Inclusion Criteria:

  • Eligible subjects will be currently pregnant women residing in the US who: Have had any exposure to Nplate® at any time during the pregnancy, which is defined as the period between first day of the last menstrual period (LMP) (ie, within two weeks of conception) up to any date before the date of delivery or end of the pregnancy. The date of conception will be defined as fourteen days prior to the next expected menstrual period for women who report a regular menstrual cycle. If the date of the first day of the LMP is unclear, or if the estimated date of conception as determined by a first-trimester ultrasound differs by more than one week from the date as determined by the first day of LMP, the first-trimester ultrasound-derived date will be used to estimate the timing of exposure to Nplate®, as well as timing of enrollment. If neither a clear date of the first day of the LMP nor a first-trimester ultrasound is available, the estimated date of conception for purposes of enrollment will be determined by best estimate of the woman's prenatal care provider.
  • Agree to enroll at any time from the estimated date of conception up to any date before the date of delivery or end of the pregnancy and who have not already had prenatal diagnosis of any major structural birth defect in the current pregnancy prior to enrollment.
  • Agree to provide consent for participation in the registry including follow-up interviews.

Exclusion Criteria:

  • Subjects will be ineligible for study participation if any of the following apply:
  • Exposure to Nplate® did not occur during pregnancy.
  • Prior knowledge of prenatal diagnosis of a birth defect. Patients who fall under this category will be encouraged to call the Amgen PSP toll free number for enrollment and follow-up.
  • Cases reported to the NPER after completion of the exposed pregnancy. Patients who fall under this category will be encouraged to call the Amgen PSP toll free number for enrollment and follow-up.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02090088


Sponsors and Collaborators
Amgen
Investigators
Layout table for investigator information
Study Director: MD Amgen
Additional Information:
Layout table for additonal information
Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT02090088    
Other Study ID Numbers: 20080046
First Posted: March 18, 2014    Key Record Dates
Results First Posted: January 6, 2015
Last Update Posted: January 6, 2015
Last Verified: December 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Abortion, Spontaneous
Congenital Abnormalities
Birth Weight
Body Weight
Pregnancy Complications